Clinical Trial Update: Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face [Phase 3]

View source ↗

Summary

Phase 3 trial assessing imiquimod as neo-adjuvant therapy to reduce excision size and intralesional excision risk in Lentigo Maligna Melanoma of the head/neck; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lentigo Maligna Melanoma

Drugs mentioned

• Imiquimod (imiquimod)

Snippet

Sponsor: Nantes University Hospital | Conditions: Lentigo Maligna Melanoma (Head or Neck) | Phase 3 | Status: COMPLETED